

AUTHOR'S REPLY

Dear Sir,

In response to the letter⁽¹⁾ commenting on our Malaysia-ACCORD study,⁽²⁾ the low prescription rates of angiotensin receptor blockers (ARB) are due to the drug policy in both the university and the Ministry of Health hospitals. The first-line treatment for hypertension or ischaemic heart disease is angiotensin converting enzymes inhibitors (ACEIs). If the patient is unable to tolerate ACEIs, only then will ARB be prescribed.

As stated by Dr Sachithanandan,⁽¹⁾ the reason for medical therapy for this cohort of patients is mainly due to the lack of resources. We have no details on the number of patients who have left main stem disease or triple-vessel disease.

Yours sincerely,

Wan Azman Wan Ahmad

Division of Cardiology
Department of Medicine
University Malaya Medical Centre
Lembah Pantai
Kuala Lumpur 59100
Malaysia
Email: wanazman@ummc.edu.my

REFERENCES

1. Sachithanandan A. Malaysia-ACCORD study: the tip of the iceberg – we must do better. *Singapore Med J* 2011; 52:702.
2. Ahmad WAW, Ramesh SV, Zambahari R. Malaysia-Acute CORonary syndromes Descriptive study (ACCORD): evaluation of compliance with existing guidelines in patients with acute coronary syndrome. *Singapore Med J* 2011; 52:508-11.